Recent developments in techniques for rapid and efficient oligonucleotide synthesis and molecular biology technology have expanded the market for manufacturers and service providers in the field. Liquid chromatography coupled with mass spectrometry (LC-MS) workflows play a critically important role.
![Attribute Monitoring Workflows [Infographic]](https://www.waters.com/blog/wp-content/uploads/feature-image-768x758.png)
Learn how the BioAccord LC-MS System is instrumental in the drug development workflow from sample prep to reporting.
Combining BioAccord, our most capable MS detection platform, with ACQUITY Premier UPLC, our highest performance LC system, to demonstrate superior performance.
The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification variants (attributes) creates an interesting analytical challenge for scientists tasked with their characterization and then with monitoring those attributes important…
To ensure compliance success in a changing regulatory landscape, laboratories must continually adapt. Learn how the compliant-ready Waters BioAccord LC-MS platform helps biopharma address the additional compliance challenges posed by the field’s complex analytical instruments.
During 2020, we collaborated with many of our customers to develop targeted liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) methods to detect SARS-CoV-2 (the virus that causes COVID-19) from biological samples. However, the combination of the biological specimen, the sample collection medium, the viral load threshold, and the need for a high throughput method gave rise to…
Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing great success as new gene-based therapeutics that hold tremendous promise. With a string of recent drug approvals, including the first…
As scientific advances continue to carry researchers into new arenas, it is vital that technology evolves in tandem. At Waters, we understand that it is only by leveraging fit-for-purpose technologies that researchers are able to unleash their creativity and make pioneering scientific breakthroughs. Scientists working within the rapidly growing biopharmaceutical industry are no exception. With…
In this series, we review considerations for keeping your lab at the forefront of science. As you adjust to living and working in a pandemic and anticipate future global and geopolitical events, Waters remains dedicated to supporting your business and unlocking the potential of your science. Our holistic separations solutions and expert support help you…
Chances are that you or someone you know has been directly impacted by breast cancer. With 2,088,849 new cases and 626,679 deaths globally,1 it is the most frequently diagnosed cancer in women in most countries (154 of 185) and is the leading cause of cancer death in women in over 100 countries. Fortunately, significant strides…
Many years ago, I was hired by a biopharma company to develop analytical methods for therapeutic oligonucleotides. When a new colleague warned me about sample loss on LC columns I looked at him with skepticism. “Yes,” he insisted, “part of your DNA sample may be irreversibly bound to the column and you will never see…
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while enhancing productivity and lowering production costs. Central to this vision are “fit-for-purpose” analytical tools working together within a single compliance-ready…